Key highlights
- Terumo will acquire WuXi Biologics' Leverkusen plant for EUR 150 million.
- The transaction is expected to close in 2025.
- WuXi Biologics will focus on expanding DP manufacturing in Singapore.
Transaction Overview
WuXi Biologics has entered into an agreement with Terumo Corporation to sell its drug product plant in Leverkusen, Germany, for EUR 150 million. The deal is anticipated to close in 2025, pending customary closing conditions.
Strategic Alignment
This divestment is part of WuXi Biologics' strategy to enhance its agility and scale diversified solutions for global clients. The company aims to address emerging needs worldwide by focusing on large-scale drug product manufacturing capacities in Singapore.
Future Focus
Following a strategic review of all its sites, WuXi Biologics will concentrate on building and developing its current locations, optimizing returns on assets for future growth.
